Phenotypes associated with this allele

• Allele Symbol: Trp73⁺
• Allele Name: wild type
• Allele ID: MGI:2437596
• Summary: 9 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
ht1	Trp73^em1(IMPC)H/Trp73^+	C57BL/6NTac-Trp73^em1(IMPC)H/H	MGI:6263779
ht2	Trp73^tm1Mak/Trp73^+	involves: 129P2/OlaHsd * C57BL/6J	MGI:3822534
ht3	Trp73^tm1Fmc/Trp73^+	involves: 129S4/SvJae * C57BL/6	MGI:5289954
ht4	Trp73^Tn(pb-Act-RFP)1.080925203-HRAZhu/Trp73^+	involves: C57BL/6	MGI:8296700
cn5	Gt(ROSA)26Sor^tm1(DTA)Riet/Gt(ROSA)26Sor^+ Reln^rl/Reln^+ Trp73^tm1(cre)Agof/Trp73^+	involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ	MGI:4365610
cn6	Gt(ROSA)26Sor^tm1(DTA)Riet/Gt(ROSA)26Sor^+ Trp73^tm1(cre)Agof/Trp73^+	involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ	MGI:4365609
cn7	Gt(ROSA)26Sor^tm1(DTA)Riet/Gt(ROSA)26Sor^+ Reln^rl/Reln^+ Trp73^tm1(cre)Agof/Trp73^+ Wnt3a^tm1(cre)Eag/Wnt3a^+	involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ	MGI:4365612
cx8	Trp53^tm1Tyj/Trp53^+ Trp73^tm1Fmc/Trp73^+	involves: 129S2/SvPas * 129S4/SvJae * C57BL/6	MGI:5289964
cx9	Trp63^tm1Fmc/Trp63^+ Trp73^tm1Fmc/Trp73^+	involves: 129S4/SvJae * C57BL/6	MGI:5289956

Genotype
MGI:6263779

ht1

• Allelic Composition: Trp73^em1(IMPC)H/Trp73⁺
• Genetic Background: C57BL/6NTac-Trp73^em1(IMPC)H/H

Data Sources

IMPC Data for Trp73

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

behavior/neurological

decreased freezing behavior ( J:211773 )

♂

IMPC - HAR

hematopoietic system

thrombocytosis ( J:211773 )

♂

IMPC - HAR

decreased spleen weight ( J:211773 )

IMPC - HAR

homeostasis/metabolism

increased blood urea nitrogen level ( J:211773 )

♀

IMPC - HAR

immune system

decreased spleen weight ( J:211773 )

IMPC - HAR

Genotype
MGI:3822534

ht2

• Allelic Composition: Trp73^tm1Mak/Trp73⁺
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6J

neoplasm

increased lymphoma incidence ( J:142848 )

• 10% of mice develop lymphoma that infiltrate more than one organ compared to 6% of wild-type mice that develop non-infiltrating lymphoma

increased T cell derived lymphoma incidence ( J:142848 )

• 5% of mice develop thymic lymphoma

increased carcinoma incidence ( J:142848 )

• 5% of mice develop colon carcinoma in situ

increased lung adenocarcinoma incidence ( J:142848 )

• 5% of mice develop lung adenocarcinoma

increased hemangiosarcoma incidence ( J:142848 )

• in 5% of mice

endocrine/exocrine glands

increased T cell derived lymphoma incidence ( J:142848 )

• 5% of mice develop thymic lymphoma

respiratory system

increased lung adenocarcinoma incidence ( J:142848 )

• 5% of mice develop lung adenocarcinoma

hematopoietic system

increased T cell derived lymphoma incidence ( J:142848 )

• 5% of mice develop thymic lymphoma

immune system

increased T cell derived lymphoma incidence ( J:142848 )

• 5% of mice develop thymic lymphoma

Genotype
MGI:5289954

ht3

• Allelic Composition: Trp73^tm1Fmc/Trp73⁺
• Genetic Background: involves: 129S4/SvJae * C57BL/6

mortality/aging

premature death ( J:98958 )

• half of heterozygous mutants are moribound by 14-15 months of age

• by 2 years of age, 36 of 40 mutants had to be sacrificed or died

• mice die from not only the malignant lesions but also from the benign lesions due to such things as obstructed airways from hyperplastic or premalignant lesions in the pharynx, larynx, mouth or tongue

neoplasm

increased tumor incidence ( J:98958 )

• mutants show an increase in benign premalignant lesions such as squamous cell hyperplasia and multiple lung adenomas

• tumors undergo loss of heterozygosity

increased T cell derived lymphoma incidence ( J:98958 )

• seen in 12.5% of mice

increased lung adenoma incidence ( J:98958 )

• frequency of lung adenomas is 4 times that seen in wild-type mice

increased malignant tumor incidence ( J:98958 )

increased lung adenocarcinoma incidence ( J:98958 )

• seen in 10% of mice

increased hemangiosarcoma incidence ( J:98958 )

• seen in 12.5% of mice

endocrine/exocrine glands

increased T cell derived lymphoma incidence ( J:98958 )

• seen in 12.5% of mice

respiratory system

increased lung adenoma incidence ( J:98958 )

• frequency of lung adenomas is 4 times that seen in wild-type mice

increased lung adenocarcinoma incidence ( J:98958 )

• seen in 10% of mice

immune system

increased T cell derived lymphoma incidence ( J:98958 )

• seen in 12.5% of mice

hematopoietic system

increased T cell derived lymphoma incidence ( J:98958 )

• seen in 12.5% of mice

Genotype
MGI:8296700

ht4

• Allelic Composition: Trp73^{Tn(pb-Act-RFP)1.080925203-HRAZhu}/Trp73⁺
• Genetic Background: involves: C57BL/6

adipose tissue

decreased total body fat amount ( J:378174 )

• male mice fail to build up regular levels of adipose tissue and exhibit less fat

• male mice show decreased fat/lean ratio, decreased fat mass/body weight ratio, decreased fat mass, and no difference in lean mass weight

decreased body fat mass ( J:378174 )

• males exhibit decreased fat mass

growth/size/body

decreased body fat mass ( J:378174 )

• males exhibit decreased fat mass

Genotype
MGI:4365610

cn5

• Allelic Composition: Gt(ROSA)26Sor^tm1(DTA)Riet/Gt(ROSA)26Sor⁺; Reln^rl/Reln⁺; Trp73^tm1(cre)Agof/Trp73⁺
• Genetic Background: involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ

nervous system

decreased Cajal-Retzius cell number ( J:153209 )

• number of Cajal-Retzius cells in the cortical marginal zone is reduced by 72% at P0

Genotype
MGI:4365609

cn6

• Allelic Composition: Gt(ROSA)26Sor^tm1(DTA)Riet/Gt(ROSA)26Sor⁺; Trp73^tm1(cre)Agof/Trp73⁺
• Genetic Background: involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ

nervous system

decreased Cajal-Retzius cell number ( J:153209 )

• number of Cajal-Retzius cells in the cortical marginal zone is reduced

Genotype
MGI:4365612

cn7

• Allelic Composition: Gt(ROSA)26Sor^tm1(DTA)Riet/Gt(ROSA)26Sor⁺; Reln^rl/Reln⁺; Trp73^tm1(cre)Agof/Trp73⁺; Wnt3a^tm1(cre)Eag/Wnt3a⁺
• Genetic Background: involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ

nervous system

decreased Cajal-Retzius cell number ( J:153209 )

• number of Cajal-Retzius cells (CRc) in the cortical marginal zone is reduced by 84% at P0

• nearly all CRc in the hippocampal formation are ablated

Genotype
MGI:5289964

cx8

• Allelic Composition: Trp53^tm1Tyj/Trp53⁺; Trp73^tm1Fmc/Trp73⁺
• Genetic Background: involves: 129S2/SvPas * 129S4/SvJae * C57BL/6

mortality/aging

premature death ( J:98958 )

• median age of survival is 6 months

neoplasm

increased metastatic potential ( J:98958 )

• about 45% of mutants develop metastatic tumors

increased tumor incidence ( J:98958 )

• mutants exhibit an increase in tumor burden compared to heterozygous Trp53 mice, with 75% of mutant mice having multiple tumors of the same or distinct types compared to only 10% in Trp53 heterozygotes

• tumors exhibit loss of heterozygosity of one or both genes

increased T cell derived lymphoma incidence ( J:98958 )

• 22.5% of mutants develop thymic lymphomas

increased pancreatic acinar cell carcinoma incidence ( J:98958 )

• 15% of mutants develop acinar pancreatic carcinoma

increased hepatocellular carcinoma incidence ( J:98958 )

• 15% of mutants develop hepatocellular carcinomas

increased lung adenocarcinoma incidence ( J:98958 )

• 10% of mutants develop lung adenocarcinomas

increased sarcoma incidence ( J:98958 )

• 50% of mutants develop sarcomas

endocrine/exocrine glands

increased T cell derived lymphoma incidence ( J:98958 )

• 22.5% of mutants develop thymic lymphomas

increased pancreatic acinar cell carcinoma incidence ( J:98958 )

• 15% of mutants develop acinar pancreatic carcinoma

respiratory system

increased lung adenocarcinoma incidence ( J:98958 )

• 10% of mutants develop lung adenocarcinomas

liver/biliary system

increased hepatocellular carcinoma incidence ( J:98958 )

• 15% of mutants develop hepatocellular carcinomas

hematopoietic system

increased T cell derived lymphoma incidence ( J:98958 )

• 22.5% of mutants develop thymic lymphomas

immune system

increased T cell derived lymphoma incidence ( J:98958 )

• 22.5% of mutants develop thymic lymphomas

Genotype
MGI:5289956

cx9

• Allelic Composition: Trp63^tm1Fmc/Trp63⁺; Trp73^tm1Fmc/Trp73⁺
• Genetic Background: involves: 129S4/SvJae * C57BL/6

mortality/aging

premature death ( J:98958 )

• mutants survive for a shorter period of time than either single mutant, with some mutants dying by 6 months of age

premature aging ( J:98958 )

• 60% of mutants exhibit increased signs of aging, developing severe degenerative disc disease of the spine between 6 and 18 months of age

neoplasm

increased metastatic potential ( J:98958 )

• about 30% of mutants develop metastatic tumors

increased tumor incidence ( J:98958 )

• tumors undergo loss of heterozygosity

• 50% of mutant mice have multiple tumors of the same or distinct types

increased salivary gland adenoma incidence ( J:98958 )

• salivary adenoma

increased T cell derived lymphoma incidence ( J:98958 )

• mutants that die by 6 months of age develop thymic lymphoma, hemangiosarcoma, or myelogenous leukemia

increased lung adenoma incidence ( J:98958 )

increased chronic myelocytic leukemia incidence ( J:98958 )

• mutants that die by 6 months of age develop myelogenous leukemia, thymic lymphoma, or hemangiosarcoma

increased carcinoma incidence ( J:98958 )

• mice that die between 6 and 12 months of age most frequently develop carcinomas

increased mammary adenocarcinoma incidence ( J:98958 )

increased lung adenocarcinoma incidence ( J:98958 )

increased squamous cell carcinoma incidence ( J:98958 )

increased hemangiosarcoma incidence ( J:98958 )

• mutants that die by 6 months of age develop hemangiosarcoma, myelogenous leukemia, or thymic lymphoma

skeleton

intervertebral disk degeneration ( J:98958 )

• 60% of mutants develop severe degenerative disc disease of the spine between 6 and 18 months of age

• degenerative disc disease is consistent with spondylosis and is most frequent in the cervical and thoracic region

behavior/neurological

paralysis ( J:98958 )

• in 10% of mutants, degenerative disc disease is so severe, it results in partial paralysis

endocrine/exocrine glands

increased salivary gland adenoma incidence ( J:98958 )

• salivary adenoma

increased T cell derived lymphoma incidence ( J:98958 )

• mutants that die by 6 months of age develop thymic lymphoma, hemangiosarcoma, or myelogenous leukemia

increased mammary adenocarcinoma incidence ( J:98958 )

respiratory system

increased lung adenoma incidence ( J:98958 )

increased lung adenocarcinoma incidence ( J:98958 )

integument

increased mammary adenocarcinoma incidence ( J:98958 )

digestive/alimentary system

increased salivary gland adenoma incidence ( J:98958 )

• salivary adenoma

hematopoietic system

increased T cell derived lymphoma incidence ( J:98958 )

• mutants that die by 6 months of age develop thymic lymphoma, hemangiosarcoma, or myelogenous leukemia

immune system

increased T cell derived lymphoma incidence ( J:98958 )

• mutants that die by 6 months of age develop thymic lymphoma, hemangiosarcoma, or myelogenous leukemia

craniofacial

increased salivary gland adenoma incidence ( J:98958 )

• salivary adenoma

growth/size/body

increased salivary gland adenoma incidence ( J:98958 )

• salivary adenoma